RXi Pharmaceuticals Corp Stock Nasdaq
Equities
US74979C5013
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.56M |
---|---|---|---|---|---|
Net income 2024 * | -13M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.22
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.41% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 12-06-18 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 17-09-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 12-06-18 |
Director/Board Member | 73 | 22-05-01 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 13-04-17 |
1st Jan change | Capi. | |
---|---|---|
+26.28% | 48.09B | |
-3.99% | 40.43B | |
+46.85% | 40.62B | |
-6.20% | 28.36B | |
+6.36% | 24.89B | |
-21.47% | 19.01B | |
+27.58% | 12.09B | |
-2.75% | 11.8B | |
-2.02% | 11.88B |